Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 697-702

  Xu, Yimin ^a   Zhong, Zhiwei ^a   Yuan, Jun ^a   Zhang, Ziheng ^a   Wei, Quantang ^a   Song, Weizheng ^a   Chen, Hongwu ^a  

^a SHANTOU UNIVERSITY   (China)

Author keywords

Glioma; Immunochemistry; Matrix metalloproteinase 1; Prognosis; Vascular endothelial growth factor C

Indexed keywords

INTERSTITIAL COLLAGENASE; VASCULOTROPIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TISSUE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EPILEPSY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

GLIOMA; IMMUNOCHEMISTRY; MATRIX METALLOPROTEINASE-1; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR-C;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CHILD; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 84884166098     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.06.006     Document Type: Article

References (35)

1. Ohgaki H., Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005, 109:93.
2. Louis D.N., Ohgaki H., Wiestler O.D. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007, 114:97-109.
3. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009, 472:323-342.
4. Zhang X., Yang H., Gong B., Jiang C., Yang L. Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. J Neurooncol 2012, 107:281-288.
5. Curran W.J., Scott C.B. Radiosurgery for glioma patients: hope or hype?. Int J Radiat Oncol Biol Phys 1996, 36:1279-1280.
6. García M., González-Reyes S., González L., Junquera S., Berdize N., Del Casar J., et al. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Path 2010, 91:324-334.
7. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
8. Hesek D., Toth M., Meroueh S., Brown S., Zhao H., Sakr W., et al. Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol 2006, 13:379-386.
9. Deryugina E., Quigley J. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
10. Del Casar J., González-Reyes S., González L., González J., Junquera S., Bongera M., et al. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol 2010, 136:811-819.
11. Pullen N.A., Fillmore H.L. Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol 2010, 96:201-209.
12. Anand M., Van Meter T.E., Fillmore H.L. Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J Neurooncol 2011, 104:679-687.
13. Malik N., Kumar R., Prasad K.N., Kawal P., Srivastava A., Mahapatra A.K. Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population. J Neurooncol 2011, 102:347-352.
14. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, vegf-c, is a ligand for the flt4 (vegfr-3) and kdr (vegfr-2) receptor tyrosine kinases. EMBO J 1996, 15:290-298.
15. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O., et al. A recombinant mutant vascular endothelial growth factor-c that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 1998, 273:6599-6602.
16. Iwasaka C., Tanaka K., Abe M., Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996, 169:522-531.
17. Grau S.J., Trillsch F., Herms J., Thon N., Nelson P.J., Tonn J.C., et al. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 2007, 82:141-150.
18. Xu Y., Yuan J., Zhang Z., Lin L., Xu S. Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis. Mol Biol Rep 2012, 39:8979-8985.
19. Stetler-Stevenson W.G., Kleiner D.E. Molecular biology of cancer: invasion and metastases. Cancer: principles and practice of oncology 2001, 123-136. Lippincott Williams and Willkins, Philadelphia7. 6th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
20. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
21. Iida J., McCarthy J.B. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res 2007, 17:205-213.
22. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003, 114:33-45.
23. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998, 185:256-261.
24. Ala-aho R., Kahari V.M. Collagenases in cancer. Biochimie 2005, 87:273-286.
25. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996, 2:461-462.
26. Nakopoulou L., Giannopoulou I., Gakiopoulou H., Liapis H., Tzonou A., Davaris P.S. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999, 30:436-442.
27. Ito T., Ito M., Shiozawa J., Naito S., Kanematsu T., Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999, 12:669-674.
28. Coso S., Zeng Y., Opeskin K., Williams E.D. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS ONE 2012, 7:e39558.
29. Cheng D., Liang B., Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS ONE 2013, 8:e55309.
30. Nakamura Y., Yasuoka H., Tsujimoto M., Imabun S., Nakahara M., Nakao K., et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005, 91:125-132.
31. Gou H.F., Chen X.C., Zhu J., Jiang M., Yang Y., Cao D., et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011, 30:14.
32. Guo X., Chen Y., Xu Z., Qian Y., Yu X. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2009, 41:217-222.
33. Li X., Liu B., Xiao J., Yuan Y., Ma J., Zhang Y. Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer. J Gastrointest Surg 2011, 15:2001-2010.
34. Ueda M., Hung Y.C., Terai Y., Kanda K., Kanemura M., Futakuchi H., et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005, 11:3225-3232.
35. Yang J., Wu H.F., Qian L.X., Zhang W., Hua L.X., Yu M.L., et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl 2006, 8:169-175.